Drug intelligence / Profile preview

JY301

Development stage: Preclinical
Lead developer: Jinyang Pharm
Modality: Small Molecules
Administration: Oral

Overview

JY301 is a small molecule sodium-glucose cotransporter 2 (SGLT2) inhibitor being developed by Jinyang Pharmaceutical for the treatment of diabetes. By targeting SGLT2 in the proximal tubules of the kidneys, the drug prevents the reabsorption of filtered glucose into the bloodstream, thereby promoting its excretion through urine (glucosuria). This insulin-independent mechanism helps lower glycated hemoglobin (HbA1c) levels and may provide additional benefits such as weight reduction and blood pressure lowering. Currently, JY301 is in the preclinical stage of development within Jinyang Pharmaceutical's metabolic disease pipeline.

Targets

SGLT2 (Sodium-glucose cotransporter protein subunit 2)

Beyond the preview

Go deeper on JY301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JY301.

Explore the full profile